Antifungal Activity and Pharmacokinetics of Posaconazole (SCH 56592) in Treatment and Prevention of Experimental Invasive Pulmonary Aspergillosis: Correlation with Galactomannan Antigenemia

The antifungal efficacy, safety, and pharmacokinetics of posaconazole (SCH 56592) (POC) were investigated in treatment and prophylaxis of primary pulmonary aspergillosis due to Aspergillus fumigatus in persistently neutropenic rabbits. Antifungal therapy consisted of POC at 2, 6, and 20 mg/kg of bod...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Petraitiene, Ruta, Petraitis, Vidmantas, Groll, Andreas H., Sein, Tin, Piscitelli, Stephen, Candelario, Myrna, Field-Ridley, Aida, Avila, Nilo, Bacher, John, Walsh, Thomas J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society for Microbiology 2001
Pynciau:
Experimental Therapeutics
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC90385/
https://ncbi.nlm.nih.gov/pubmed/11181372
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.45.3.857-869.2001
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg